Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluvastatin in High-Risk Melanoma
NCT04285749Phase 1Withdrawn
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Nov 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of fluvastatin in Malignant Melanoma (MM), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Genetic profile shift in melanoma transcriptome at 2 weeks. Planned start Nov 2020; status: withdrawn.
02
Drugs
fluvastatin
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT04285749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04285749.